ATNM News and Press, Actinium Pharmaceuticals Inc. From 02/22/23

Palm Beach, FL – February 22, 2023 – FinancialNewsMedia.com News Commentary – Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of cancer that mainly occurs in white blood cells. White bloo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time to start another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are a $30 million private placement,...

Actinium Pharmaceuticals ( NYSE: ATNM ) added ~13% pre-market Monday after announcing its pivotal Phase 3 trial for lead candidate Iomab-B reached the primary endpoint in active relapsed or refractory acute myeloid leukemia (r/r AML). The 153-patient SIERRA trial was designed to e...

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia PR Newswire -  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial compl...

Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023 Actinium to Present Full Results from Pivotal Phase 3 Iom...

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies PR Newswire -  National Cancer I...

Summary Today, we take our first new look at a small developmental firm called Actinum Pharmaceuticals in nearly two years. The company posted promising results from a pivotal trial around its lead candidate in October and should soon submit a Biologic License Application around the com...

Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference PR Newswire NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the developmen...

Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem ...

Summary Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators. The sell-off over the data delay is overdone. Shares have drifted down from a November high of $14.41 to $9.88, offering an interest...